The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis

BMC Endocrine Disorders

Jiayu Gu¹  Siyu Chen¹  Xia Wen¹  Yunzhi Zou¹  Depei Li¹  Xiaobing Jiang²  Jiajun Dong³ 

[1] Department of Neurosurgery/Neuro-oncology, Sun Yat-sen University Cancer Center. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 510060, Guangzhou, China;Department of Neurosurgery/Neuro-oncology, Sun Yat-sen University Cancer Center. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 510060, Guangzhou, China;Jiangmen Central Hospital, Affiliated Jiangmen hospital of Sun Yat-Sen University, 519000, Jiangmen, China;Jiangmen Central Hospital, Affiliated Jiangmen hospital of Sun Yat-Sen University, 519000, Jiangmen, China;

关键词: Prolactinoma;    Dopamine agonist;    Cabergoline;    Bromocriptine;    Recurrence;    Meta-analysis;   

DOI  :  10.1186/s12902-021-00889-1

来源: Springer

【 摘 要 】

BackgroundProlactinoma is the major cause of hyperprolactinemia, and dopamine agonists (DAs) are generally the first-line treatment for them. Several studies have reviewed the recurrent rate of hyperprolactinemia after DAs withdrawal. However, few of them have concerned the recurrence risk of prolactinoma following the withdrawal of DAs.MethodsThree medical databases, PubMed, EMBASE and Cochrane library, were retrieved up to February, 14, 2021 to identify studies related to recurrence of prolactinoma and withdrawal of DAs. Statistical analyses including meta-analysis, sensitivity analysis, meta-regression, funnel plot and Egger test were performed through software R.ResultsA total of 3225 studies were retrieved from the three data bases, and 13 studies consisted of 616 patients and 19 arms were finally included in this systematic analysis. There was no significant heterogeneity among the included studies, and fixed effect model was thus used. The pooled recurrence proportion of prolactinoma after withdrawal of DA was 2% with a 95% confidence interval (CI) of 1–3%.ConclusionOur study showed a very low recurrent rate of prolactinomas after DAs withdrawal. Much more prospective studies with larger cases and longer follow-up period are encouraged to confirm our finding.Trial registrationRegistration numberCRD42021245888 (PROSPERO).

【 授权许可】

CC BY